Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 6, 2010, Pages 597-603

  Renieri, Giulia ^a   Führer, Katrin ^b   Scheithe, Karl ^b   Lorenz, Katrin ^a   Pfeiffer, Norbert ^a   Thieme, Hagen ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Abteilung Biostatistik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; BIMATOPROST; BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; BRINZOLAMIDE; COSOPT S; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; EYE DROPS; LATANOPROST; LATANOPROST PLUS TIMOLOL; METIPRANOLOL; PRESERVATIVE; TIMOLOL; TIMOLOL PLUS TRAVOPROST; TRAVOPROST; UNCLASSIFIED DRUG;

AGED; ANGINA PECTORIS; ARTICLE; BURNING EYE; BURNING SENSATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GLAUCOMA; HUMAN; HYPEREMIA; INFECTION RISK; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; SIDE EFFECT;

ADMINISTRATION, TOPICAL; AGED; ANTIHYPERTENSIVE AGENTS; BENZALKONIUM COMPOUNDS; DRUG COMBINATIONS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; HYPEREMIA; INTRAOCULAR PRESSURE; MALE; OPHTHALMIC SOLUTIONS; PRESERVATIVES, PHARMACEUTICAL; PROSPECTIVE STUDIES; SULFONAMIDES; THIOPHENES; TIMOLOL; TREATMENT OUTCOME;

EID: 78649694589     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0060     Document Type: Article

References (22)

1. Wilson, L.A. To preserve or not to preserve, is that the question? Br. J. Ophthalmol. 80:583-584, 1996.
2. Brandt, J.D., Wittpenn, J.R., Katz, L.J., et al. Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Am. J. Ophthalmol. 112:297-301, 1991.
3. Wilson, F.M., 2nd. Adverse external ocular effects of topical ophthalmic medications. Surv. Ophthalmol. 24:57-88, 1979.
4. Mietz, H., Niesen, U., and Krieglstein, G.K. The effect of preservatives and antiglaucomatous medication on the his-topathology of the conjunctiva. Graefes Arch. Clin. Exp. Ophthalmol. 232:561-565, 1994.
5. Noecker, R.J., Herrygers, L.A., and Anwaruddin, R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 23:490-496, 2004.
6. De Saint Jean, M., Brignole, F., Bringuier, A.F., et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest. Ophthalmol. Vis. Sci. 40:619-630, 1999.
7. Ayaki, M., Yaguchi, S., Iwasawa A., et al. Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells. Clin. Exp. Ophthalmol. 36:553-559, 2008.
8. Gasset, A.R., Ishii, Y., Kaufman, H.E., et al. Cytotoxicity of ophthalmic preservatives. Am. J. Ophthalmol. 78:98-105, 1974.
9. Burstein, N.L. Preservative cytotoxic threshold for benzalk-onium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest. Ophthalmol. Vis. Sci. 19:308-313, 1980.
10. Baudouin, C., and de Lunardo, C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br. J. Ophthalmol. 82:39-42, 1998.
11. Kuppens, E.V., de Jong, C.A., Stolwijk, T.R., et al. Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Br. J. Ophthalmol. 79:339-342, 1995.
12. Baudouin, C., Pisella, P.J., Fillacier, K., et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 106:556-563, 1999.
13. Erb, C., Gast, U., and Schremmer, D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch. Clin. Exp. Ophthalmol. 246:1593-1601, 2008.
14. Lavin, M.J., Wormald, R.P., Migdal, C.S., et al. The influence of prior therapy on the success of trabeculectomy. Arch. Ophthalmol. 108:1543-1548, 1990.
15. Broadway, D., Grierson, I., and Hitchings, R. Adverse effects of topical antiglaucomatous medications on the conjunctiva. Br. J. Ophthalmol. 77:590-596, 1993. (Pubitemid 23281461)
16. Broadway, D.C., Grierson, I., O'Brien, C., et al. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch. Ophthalmol. 112:1446-1454, 1994. (Pubitemid 24350507)
17. Kawa, J.E., Higginbotham, E.J., Chang, I.L., et al. Effects of antiglaucoma medications on bovine trabecular meshwork cells in vitro. Exp. Eye Res. 57:557-565, 1993.
18. Jaenen, N., Baudouin, C., Pouliquen, P., et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur. J. Ophthalmol. 17:341-349, 2007.
19. Mundorf, T.K., Ogawa, T., Naka, H., et al. A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertension. Clin. Ther. 26:541-551, 2004.
20. Manni, G., Centofanti, M., Oddone, F., et al. Interleukin-1beta tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonse-lective beta-blockers. Am. J. Ophthalmol. 139:72-77, 2005.
21. Baudouin, C. Allergic reaction to topical eyedrops. Curr. Opin. Allergy Clin. Immunol. 5:459-463, 2005.
22. Pisella, P.J., Pouliquen, P., and Baudouin, C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br. J. Ophthalmol. 86:418-423, 2002. (Pubitemid 34293291)